قالب وردپرس درنا توس
Home / Health / Common blood pressure medication associated with increased risk of lung cancer

Common blood pressure medication associated with increased risk of lung cancer




<div _ngcontent-c14 = "" innerhtml = "

Based on the results of an observational study published earlier this week in The BMJ angiotensin converting enzyme (ACE) inhibitors were associated with an elevated level Risk of lung cancer compared to a similar but different type of blood pressure medication known as angiotensin receptor blockers (ARBs)

Lisinopril, molecular model, angiotensin converting enzyme (ACE) class of drugs for the treatment of hypertension The atoms are represented as spheres and are color-coded: carbon (gray), hydrogen (white), nitrogen (blue), and oxygen (red) (courtesy of Getty Images) [19659002] Researchers evaluated patients a UK database of primary care and identified more than 900,000 adults who were treated with any kind of from 1995 to 2015 Blood pressure medication started. They excluded patients with a history of cancer.

Over 335,000 patients were treated with ACE i inhibitors, 29,000 with ARBs and 101,000 with an ACE and ARB inhibitor. Ramipril (26%), along with lisinopril (12%) and perindopril (7%), were the most frequently observed ACE in the study.

Over a follow-up period of 6 years, lung cancer was diagnosed in 0.8% (7,952) of this 900,000-person cohort. After considering smoking and other potential confounders, the use of ACE inhibitors was associated with a 14% higher risk of lung cancer compared to ARB (1.6 vs. 1.2 per 1000 person-years). In a secondary analysis, the use of an ACE inhibitor for less than 5 years was not associated with an increased risk of lung cancer.

However, the study found that the increased risk only occurred in one patient over a 5-year period on an ACE inhibitor however, increased with more than 10 years of use (31% increased risk ).

In their study, researchers said the use of ACE inhibitors to accumulate bradykinin in the lungs has been reported to stimulate the growth of lung cancer. The use of ACE inhibitors may also lead to increased concentrations of a compound known as substance P produced in lung cancer cells and associated with tumor growth

Given this data, it is important for the public to understand that this is only one Observational study is – not a randomized, double-blind, placebo-controlled trial – that lowers the absolute risk to patients Data indicates that A CE inhibitors make up nearly a third of all blood pressure medicines that are prescribed in the UK, which results for a large number of patients becoming a potential problem.

While ACE inhibitors are highly effective drugs for the treatment of hypertension. Www.celesio.com/ag/?redirect=true&n…id=4&nx=1665 There have also been concerns regarding the safety of their long – term use, in particular in the field of Related to increased lung cancer risk.

In addition, observational studies have led to mixed findings (relative to the actual lung cancer risk compared to the overall risk of cancer)), with no clear consensus so far, and meta-analyzes of randomized controlled trials have found no evidence of increased cancer risk due to small sample size and length of follow-up (median of 3.5 years) compromising validity of findings [19659003] Important limitations of the study that should be mentioned are lack of information on socioeconomic status, diet, exposure to asbestos or radon, and family history of lung cancer for patients nts included in the study. The authors also had no detailed information on the number of pack years of smoking, an important risk factor for the incidence of lung cancer.

However, there is biochemical evidence supporting a possible association between ACE inhibitors and risk of lung cancer with elevated levels of bradykinin and substance P, which could facilitate the growth of lung cancer.

Certainly, in every lung cancer risk patient, the benefits associated with taking an ACE inhibitor to lower blood pressure and cardiac risk must be weighed against the risk of lung cancer.

This opinion is shared by an expert who was concerned about the risks associated with ACE inhibitors.

"This high-quality study shows that ACE inhibitors are a risk factor for lung cancer," said Klaus Lessnau, MD, Pulmonary and Intensive Care Specialist at Lenox Hill Hospital in New York City.

"The most important factor remains smoking, but implies that ACE inhi Bitoren should be contraindicated in smokers and ex-smokers, armed with a study that revealed significant statistical association and biological plausibility," Lessnau offered. "" Man wonders if they should be continued on non-smokers, "he added.

This study is based on the large number of patients currently taking long-term ACE inhibitors and the associated concerns about increased cancer risk and the potential need to change their medication based on the results of this study

Again, it is important to emphasize that this is an observational study and the overall risk to patients is relatively low the risks and benefits of staying with an ACE inhibitor One option could be to to transition to the ARB if there is continuing concern, as no increased lung cancer risk has been observed in this class of antihypertensive drugs. ARBs can actually reduce the risk of lung cancer with a protective effect, based on recent studies.

In an accompanying Editorial in BMJ Dr. Deirdre Cronin-Fenton, Associate Professor, Department of Clinical Epidemiology, Aarhus University in Denmark, reports the findings, but recommends the need for further studies to validate the results of this prospective observational cohort study.

Cronin – Fenton writes that the study "estimates the value of English:. German: v3.espacenet.com/textdoc? % could not lead to a large absolute risk, the results are significant in view of the data available for the study significant use of ACE inhibitors worldwide. "

Cronin-Fenton continues:" Nevertheless, should at one While individual patients' concerns about long-term lung cancer risk, such as [the authors] associated with the use of ACE inhibitors, now require further long-term follow-up studies to improve the scientific evidence of long-term safety of these drugs. "

ACE inhibitors were certainly helpful in controlling blood pressure While this study highlights a biochemical mechanism that exists, the data is still be care of nature and require more in-depth investigations to make a definite decision regarding the decision to terminate and replace them in favor of a new class

">

Based on the results of an observational study earlier this week In The BMJ was published, angiotensin converting enzyme (ACE) inhibitors were associated with an increased risk of lung cancer, compared with a similar but different type of blood pressure medication called angiotensin receptor blocker ( ARBs) are known.

Lisinopril, molecular model. Angiotensin converting enzyme (ACE) class of medicines used in the treatment of hypertension, congestive heart failure and myocardial infarction. Atoms are represented as spheres and marked in color: carbon (gray), hydrogen (white), nitrogen (blue) and oxygen (red). (19659002) Researchers evaluated patients from a UK Primary Care database and identified over 900,000 adults who had started any type of blood pressure medication from 1995 to 2015. They excluded patients with a history of cancer.

Over 335,000 patients were treated with ACE inhibitors, 29,000 with ARBs and 101,000 with an ACE and ARB inhibitor. Ramipril (26%) was the most commonly observed ACE along with lisinopril (12%) and perindopril (7%).

Over a six-year follow-up period, lung cancer was diagnosed in 0.8% (7,952) of this 900,000-person cohort. After considering smoking and other potential confounders, the use of ACE inhibitors was associated with a 14% higher risk of lung cancer compared to ARB (1.6 vs. 1.2 per 1000 person-years). In a secondary analysis, the use of an ACE inhibitor for less than 5 years was not associated with an increased risk of lung cancer.

However, the study found that the increased risk only occurred in one patient over a 5-year period on an ACE inhibitor however, increased with more than 10 years of ingestion (31% increased risk ).

In their study, researchers said the use of ACE inhibitors to accumulate bradykinin in the lungs was reported to "stimulate the growth of lung cancer". The use of ACE inhibitors may also lead to increased concentrations of a compound known as substance P, produced in lung cancer cells and associated with tumor growth

Given this data, it is important for the public to understand that Only One Observational Study – No Randomized, Double-blind, Placebo-Controlled Trial – That Lowers the Absolute Risk for Patients Data show that A CE inhibitors make up nearly a third of all the blood pressure medications that are prescribed in the UK, which results for one large number of patients becoming a potential problem.

While ACE inhibitors are highly effective drugs for the treatment of hypertension. Www.celesio.com/ag/?redirect=true&n…id=4&nx=1665 There have also been concerns regarding the safety of their long – term use, in particular in the field of Related to increased lung cancer risk.

In addition, observational studies have led to mixed findings (relative to the actual lung cancer risk compared to the overall risk of cancer)), with no clear consensus so far, and meta-analyzes of randomized controlled trials have found no evidence of increased cancer risk due to small sample size and length of follow-up (median of 3.5 years) compromising validity of findings [19659003] Important limitations of the study that should be mentioned are lack of information on socioeconomic status, diet, exposure to asbestos or radon, and family history of lung cancer for patients nts included in the study. The authors also had no detailed information on the number of pack years of smoking, an important risk factor for the incidence of lung cancer.

There is, however, biochemical evidence supporting a possible association between ACE inhibitors and risk of lung cancer with elevated levels of bradykinin and substance P, which could facilitate the growth of lung cancer

Certainly, for every lung cancer risk patient, the benefits associated with taking an ACE inhibitor to lower blood pressure and cardiac risk must be weighed against the risk of lung cancer.

This opinion is shared by an expert who was concerned about the risks associated with ACE inhibitors.

"This high-quality study shows that ACE inhibitors are a risk factor for lung cancer," said Klaus Lessnau, MD, Pulmonary and Intensive Care Specialist at Lenox Hill Hospital in New York City.

"The most important factor remains smoking, but implies that ACE inhi Bitoren should be contraindicated in smokers and ex-smokers, armed with a study that revealed significant statistical association and biological plausibility," Lessnau offered. "" Man wonders if they should be continued on non-smokers, "he added.

This study is based on the large number of patients currently taking long-term ACE inhibitors and the associated concerns about increased cancer risk and the potential need to change their medication based on the results of this study

Again, it is important to emphasize that this is an observational study and the overall risk to patients is relatively low the risks and benefits of staying with an ACE inhibitor One option could be to to transition to the ARB if there is continuing concern, as no increased lung cancer risk has been observed in this class of antihypertensive drugs. ARBs can actually reduce the risk of lung cancer with a protective effect, based on recent studies.

In an accompanying Editorial in BMJ Dr. Deirdre Cronin-Fenton, Associate Professor, Department of Clinical Epidemiology, Aarhus University in Denmark, reports the findings, but recommends the need for further studies to validate the results of this prospective observational cohort study.

Cronin – Fenton writes that the study "estimates the value of English:. German: v3.espacenet.com/textdoc? % could not lead to a large absolute risk, the results are significant in view of the data available for the study significant use of ACE inhibitors worldwide. "

Cronin-Fenton continues:" Nevertheless, should at one While individual patients' concerns about long-term lung cancer risk, such as [the authors] associated with the use of ACE inhibitors, now require further long-term follow-up studies to improve the scientific evidence of long-term safety of these drugs. "

ACE inhibitors were certainly helpful in controlling blood pressure While this study highlights a biochemical mechanism that exists, the data is still be of a more caring nature and require more in-depth investigation to make a definitive decision regarding the decision to end it in favor of a new class and replace medication for blood pressure control.


Source link